| Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 3 HR (95% CI) |
---|---|---|---|
Methadone | 1.33 (0.58–3.05) | 1.22 (0.53–2.80) | 1.18 (0.49–2.83) |
Randomized allocation phase | 1.99 (0.82–4.84) | 1.84 (0.76–4.46) | 1.65 (0.58–4.67) |
Methadone*allocation phase | 0.69 (0.21–2.23) | 0.70 (0.22–2.24) | 0.66 (0.19–2.32) |
HHRP | 1.34 (0.81–2.22) | 1.30 (0.78–2.17) | 0.99 (0.56–1.76) |
Age (years) |  |  | 0.98 (0.93–1.04) |
Malay ethnicity |  |  | 0.61 (0.29–1.29) |
Married |  |  | 1.97 (0.92–4.21) |
Educational attainment |  |  | 1.35 (1.04–1.76) |
Employed†|  |  | 0.59 (0.33–1.04) |
CD4+ T-cell count‡ |  | 0.90 (0.82–1.00) | 0.84 (0.72–0.97) |
HIV symptom index |  |  | 0.97 (0.90–1.05) |
History of tuberculosis |  |  | 0.55 (0.24–1.27) |
Addiction severity index§ |  |  | 0.98 (0.95–1.02) |
History of drug injection |  |  | 1.05 (0.38–2.90) |
Benzodiazepine use†|  |  | 1.82 (0.81–4.13) |
Methamphetamine use†|  |  | 0.83 (0.42–1.62) |
Opioid use†|  |  | 2.50 (0.56–11.1) |
Alcohol use†|  |  | 2.02 (1.06–3.86) |